百奥泰生物制药股份有限公司关于公司2026年度日常关联交易预计的公告

Core Viewpoint - The announcement details the expected daily related transactions for the year 2026 by Baotai Biopharmaceutical Co., Ltd., emphasizing that these transactions are necessary for normal business operations and do not harm the interests of the company or minority shareholders [2][10]. Group 1: Daily Related Transactions Overview - The expected daily related transactions do not require shareholder meeting approval, as they fall within the board's authority [5]. - The board of directors approved the expected daily related transactions for 2026 during a meeting held on December 29, 2025, with non-related directors voting unanimously in favor [3]. - Independent directors also reviewed and approved the expected transactions, confirming that they align with the company's operational needs and adhere to principles of fairness and market pricing [4]. Group 2: Transaction Amounts and Categories - The expected transaction amounts for 2026 are presented in ten thousand yuan, with specific categories including leasing properties, purchasing technical services, and selling goods to related parties [6][8]. - The transactions are based on voluntary, equal, and mutually beneficial principles, with prices set according to market rates [9]. Group 3: Purpose and Impact of Transactions - The related transactions are essential for the company's normal production and operations, serving as a means to optimize resource use and reduce operational costs [10]. - The pricing policies for these transactions strictly follow principles of openness, fairness, and equivalence, ensuring no adverse effects on the company's ongoing operations, profitability, or asset independence [10].